Evidence map›Paper›PMID 38294250›Full record

ArticleJournal of virology2024

Establishment of a novel human T-cell leukemia virus type 1 infection model using cell-free virus.

Koh Nagata, Kenta Tezuka, Madoka Kuramitsu, Naoki Fuchi, Yuri Hasegawa, Isao Hamaguchi, Kiyonori Miura

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Koh Nagata *Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kenta Tezuka *Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0009-0000-3592-4981
Madoka KuramitsuResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-3064-5219
Naoki FuchiDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yuri HasegawaDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Isao HamaguchiResearch Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Tokyo, Japan.
Kiyonori MiuraDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
National Institute of Infectious Diseases · JPNagasaki University · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP22fk0108124jJapan Agency for Medical Research and Development (AMED) JP23fk0108671jMEXT | Japan Society for the Promotion of Science (JSPS) 22K08594
6 · The paper itself

Abstract

The primary mode of infection by human T-cell leukemia virus type 1 (HTLV-1) is cell-to-cell transmission during contact between infected cells and target cells. Cell-free HTLV-1 infections are known to be less efficient than infections with other retroviruses, and transmission of free HTLV-1 is considered not to occur

Indexed as

Cell-Free SystemHTLV-I InfectionsHuman T-lymphotropic virus 1AnimalsBiofilmsCell LineCells, CulturedHumansLymphocytesMiceProvirusesReverse TranscriptionVirus IntegrationVirus InternalizationVirus Replicationcell-free HTLV-1 infectionHTLV-1 infectious molecular cloneHTLV-1-producing cellshumanized mouse modelviral replication cycle

Identifiers

PMID38294250
PMCPMC10878273
OpenAlexW4391386592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.